Jump to main content
Jump to site search

Issue 3, 2011
Previous Article Next Article

A pretargeted nanoparticle system for tumor cell labeling

Author affiliations

Abstract

Nanoparticle-based cancer diagnostics and therapeutics can be significantly enhanced by selective tissue localization, but the strategy can be complicated by the requirement of a targeting ligand conjugated on nanoparticles, that is specific to only one or a limited few types of neoplastic cells, necessitating the development of multiple nanoparticle systems for different diseases. Here, we present a new nanoparticle system that capitalizes on a targeting pretreatment strategy, where a circulating fusion protein (FP) selectively prelabels the targeted cellular epitope, and a biotinylated iron oxide nanoparticle serves as a secondary label that binds to the FP on the target cell. This approach enables a single nanoparticle formulation to be used with any one of existing fusion proteins to bind a variety of target cells. We demonstrated this approach with two fusion proteins against two model cancer cell lines: lymphoma (Ramos) and leukemia (Jurkat), which showed 72.2% and 91.1% positive labeling, respectively. Notably, TEM analysis showed that a large nanoparticle population was endocytosed via attachment to the non-internalizing CD20 epitope.

Graphical abstract: A pretargeted nanoparticle system for tumor cell labeling

Back to tab navigation

Supplementary files

Publication details

The article was received on 19 Apr 2010, accepted on 13 Oct 2010 and first published on 24 Nov 2010


Article type: Paper
DOI: 10.1039/C005154C
Citation: Mol. BioSyst., 2011,7, 742-748
  •   Request permissions

    A pretargeted nanoparticle system for tumor cell labeling

    J. Gunn, S. I. Park, O. Veiseh, O. W. Press and M. Zhang, Mol. BioSyst., 2011, 7, 742
    DOI: 10.1039/C005154C

Search articles by author

Spotlight

Advertisements